Adolescents
Psychedelic use among adolescents presents a complex interplay between cultural context, potential therapeutic benefits, and risks associated with mental health. Recent research suggests that while Western perspectives are largely negative, there is a growing interest in the potential for psychedelics to support mental health treatment in this demographic, particularly in therapeutic settings.
What is Adolescents?
Adolescence, typically ranging from ages 10 to 19, is a critical period for brain development and mental health. The neuroplasticity of the adolescent brain may make it particularly vulnerable to the effects of psychoactive substances, including psychedelics. Common psychological issues during this stage include mood disorders, anxiety, and risk-taking behaviours, which can be exacerbated by substance use.
Adolescents may use psychedelics both recreationally and within cultural or therapeutic frameworks. Psychotropic substances like MDMA and ayahuasca are sometimes employed in ritualistic contexts within certain cultures, and evidence suggests that such contexts might mitigate risks.
Currently, there is a scarcity of rigorous studies examining the impact of psychedelic use on adolescent mental health, necessitating further exploration. The contrasting cultural reception of psychedelics indicates a need for a nuanced understanding of their effects across different societal settings.
Current Treatments
Standard treatments for mental health issues in adolescents primarily involve psychotherapy, medication (such as SSRIs), and lifestyle modifications. More recently, there is increasing interest in exploring the therapeutic potential of psychedelics, particularly for conditions like anxiety and PTSD among young patients.
Psychedelic Effect Matrix
Systematic comparison of compound efficacy and evidence levels for Adolescents.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| MDMA There are emerging clinical findings supporting its utility in psychotherapy for adolescents, but robust clinical trials are still required. | Medium | Moderate | Inconsistent |
| Ayahuasca Initial studies suggest ayahuasca may lower psychiatric symptom risk in cultural contexts, but more controlled research is needed. | Medium | Moderate | Inconsistent |
| Psilocybin Evidence hints at its potential for improving mood disorders among adolescents, though further investigation is critically needed. | Medium | Moderate | Inconsistent |
| Ketamine Research shows promise for treatment-resistant depression in adolescents, yet methodological limitations persist. | Medium | Moderate | Inconsistent |
MDMA and Adolescents
MDMA, widely known as 'ecstasy', has been associated with increased empathy and emotional processing, making it a candidate for aiding psychotherapy in adolescents with PTSD. Initial investigations highlight that it may enhance therapeutic relationships and provide emotional release, yet concerns regarding misuse and long-term effects are evident in recreational contexts.
Ayahuasca and Adolescents
Ayahuasca, a psychoactive brew consumed culturally and spiritually among indigenous groups, has shown potential mental health benefits for adolescent users within ritualistic settings. Literature suggests that ayahuasca may provide insights into personal issues and assist in emotional healing, although its effects in uncontrolled recreational settings pose various mental health risks.
Psilocybin and Adolescents
Psilocybin, the active compound in magic mushrooms, has been explored for its efficacy in treating depression and anxiety among adolescents. Some studies suggest that it can lead to significant improvements in mood and a sense of connectedness, though rigorous clinical trials in this demographic are still in preliminary stages.
Ketamine and Adolescents
Ketamine has been noted for its rapid antidepressant effects, even among adolescents. While traditional antidepressants may take weeks to provide relief, ketamine shows promise in significantly alleviating depressive symptoms within hours in clinical settings. Its application remains under scrutiny, particularly regarding long-term safety and efficacy in younger populations.
Key Insights
- 1
Cultural context plays a significant role in the perception and outcomes of psychedelic use among adolescents.
- 2
Preliminary studies suggest that ritualistic use of ayahuasca may lower the incidence of psychiatric symptoms compared to controls.
- 3
There is a budding recognition within the clinical community of psychedelics’ therapeutic potential for treating mental health disorders in adolescents.
- 4
MDMA has been shown to foster emotional support and may improve outcomes in psychotherapy for PTSD amidst young individuals.
- 5
Research suggests that psychedelics like psilocybin may be associated with lower rates of suicidal thoughts among adolescents.
Industrial Landscape
Key organisations involved in this research space include MAPS (Multidisciplinary Association for Psychedelic Studies) and numerous academic institutions exploring the intersections of psychedelics, mental health, and adolescence. Leading researchers like Rick Doblin advocate for the responsible exploration of psychedelics in therapeutic settings.
Quick Indicators
\"Ongoing clinical evaluations are investigating Adolescents as a primary indication for various psychedelic compounds.\"
Key Organizations
4 ConnectedDelix Therapeutics
Delix Therapeutics is harnessing the power of neuroplastogens, a novel class of compounds designed to bring about a new paradigm in brain health therapeutics with treatments intended to be safe, fast-acting, and long-lasting. Through its discovery platform, Delix has identified non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. The company was co-founded in 2019 by David E. Olson and Nick Haft, building upon Olson's discovery at the University of California, Davis, of several novel psychoplastogens that have significant therapeutic potential in preclinical models, without hallucinogenic side effects. Delix's treatments are designed to address the root cause of neuropsychiatric conditions by repairing the underlying synaptic damage through targeted neuroplasticity. To date, the company has synthesized over 2000 novel psychoplastogens, many of which are analogs of known psychedelics such as ibogaine and 5-MeO-DMT. Their lead compound, zalsupindole (DLX-001), produces the same rapid and sustained structural and functional plasticity as ketamine, psilocybin, and DMT, without inducing hallucinations or dissociation. Recent Phase I data have demonstrated that DLX-001 is associated with robust signs of CNS engagement and a favorable safety and tolerability profile, with no serious adverse events reported to date. The company's compounds are tailored for swift neuronal repair and can be taken at-home, providing significant advantages to patients, their loved ones, and healthcare providers. Delix focuses on developing non-hallucinogenic psychoplastogens as scalable alternatives to first-generation hallucinogenic psychoplastogens like ketamine and psilocybin.
MAPS
The description of the stakeholder
Lykos Therapeutics
Longer description of Lykos .. lorem ipsum ..
Leiden University
Leiden University doesn't have a dedicated research centre for psychedelics. However, several staff members from their medical centre and psychology faculty are working with psychedelics. Researchers here are working with other universities including Utrecht University as well as Compass Pathways.
Prominent Researchers
1 LinkedConnected Evidence
The latest clinical data points and verified academic findings associated with Adolescents.